Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 4(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03088449Unknown

Personalising Anti-TNF Therapy in Crohns Disease (PANTS)

Role: collaborator

NCT02388373Phase 4Completed

A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down

Role: collaborator

NCT01678430Phase 3Unknown

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Role: collaborator

NCT00312195Phase 3Completed

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

Role: collaborator

NCT00784810Phase 4Completed

A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis

Role: lead

NCT00324038Phase 4Completed

Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

Role: lead

All 6 trials loaded